TriangleHEALTH PROFESSIONAL · SOURCE READING
Pembrolizumab for patients with dMMR or MSI-H tumors
Source: Gastric Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Evidence (pembrolizumab for patients with dMMR or MSI-H tumors):
In a phase II study of pembrolizumab 200 mg IV every 3 weeks in patients with colon cancer with or without dMMR, and noncolorectal cancer with dMMR, the immune-related objective response rate was 71% (5 of 7 patients). Based on these data, pembrolizumab was approved for patients with dMMR solid tumors that have progressed after previous treatment and who have no satisfactory alternative treatment options.[35]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice